A Phase I Clinical Study of Dual Specificity CD19 and CD22 Chimeric Antigen Receptor T Cell Therapy in Relapsed or Refractory Lymphoma
Phase of Trial: Phase I
Latest Information Update: 07 Jun 2019
Price : $35 *
At a glance
- Drugs LCAR L10D (Primary)
- Indications B-cell lymphoma
- Focus Adverse reactions
- 03 Mar 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 18 Feb 2018 to 10 Mar 2019.
- 10 Feb 2019 Planned number of patients changed from 12 to 9.
- 10 Feb 2019 Planned initiation date changed from 18 Sep 2018 to 18 Feb 2018.